Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series
November 10 2022 - 4:05PM
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell
reprogramming company dedicated to developing curative cell
therapies for patients with solid tumors, announced today that
members of its senior management team will participate in the
Barclays Virtual Fireside Chat Series on Thursday, November 17, at
11 a.m., ET.
A webcast of the presentation can be accessed
through the investor relations section of the Company’s website at
www.lyell.com. A replay of the webcast will be available on the
Company’s website for 90 days following the presentation.
About Lyell Immunopharma,
Inc.
Lyell is a clinical-stage T-cell reprogramming
company dedicated to developing curative cell therapies for
patients with solid tumors. The Company is advancing a pipeline of
therapies designed to address what it believes are the primary
barriers that limit consistent, reliable and curative responses to
adoptive T-cell therapy: T cell exhaustion and lack of durable
stemness, which includes the ability to proliferate, persist and
self-renew, as well as generate differentiated effector cell
progenies to provide durable anti-tumor functionality. Lyell is
applying its proprietary ex vivo genetic and epigenetic
reprogramming technologies to address these barriers in order to
develop new medicines with improved, durable and potentially
curative clinical outcomes. Lyell is based in South San Francisco,
California with facilities in Seattle and Bothell, Washington. To
learn more, please visit www.lyell.com.
Contact:Ellen RoseSenior Vice
President, Communications and Investor Relationserose@lyell.com
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From Apr 2023 to Apr 2024